| Project/Area Number |
16591241
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | National Institute of Radiological Sciences |
|---|
Principal Investigator |
KAMADA Tadashi National Institute of Radiological Sciences, Research Center Hospital, 重粒子医科学センター, 研究員 (90150242)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IMAI Reiko National Institute of Radiological Sciences, Research Center Hospital, 重粒子医科学センター, 研究員 (80385418)
TSUJII Hirohiko National Institute of Radiological Sciences, Research Center Hospital, 重粒子医科学センター, 研究員 (50088853)
TSUJI Hiroshi National Institute of Radiological Sciences, Research Center Hospital, 重粒子医科学センター, 研究員 (70207364)
ISHIKAWA Hitoshi National Institute of Radiological Sciences, Research Center Hospital, 重粒子医科学センター, 研究員 (70344918)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥3,400,000 (Direct Cost: ¥3,400,000)
Fiscal Year 2005: ¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 2004: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Keywords | sacrum / chordoma / sciatic nerve function / carbon ion radiotherapy / MATCHED PAIR STUDY |
|---|
| Research Abstract |
Background : Bone and soft tissue sarcomas (BSTSs) unsuitable for surgical resection caused severe prognosis and deterioration of function. We treated unresectable BSTSs with carbon ion radiotherapy (CIRT) and evaluated the efficacy in the aspect of quality of life (QOL).
Methods : Between April 2000 and November 2003, we enrolled 108 patients with BSTSs unsuitable for surgical resection into phase II study and treated with CIRT at the Heavy Ion Medical Accelerator in Chiba, Japan. Patients completed the EORTC-QLQ-C30 before the start of CIRT and at the end of CIRT, and follow-up questionnaires by mail 3, 6, and 12 months after CIRT.
Results : Among these 108 patients, the 1-year overall survival rate was 92%. The 1-year local control and 1-year disease-free survival rates were 95%and 68%, respectively. We further analyzed the 82 patients who completed all five questionnaires. Overall compliance was 94% throughout one year and functional and global QOL scales did not significantly change during the year.
Subset analysis found that functional and QOL levels tended to decrease more in the larger than 600 cm^3 clinical target volume (CTV) group compared with the smaller CTV group. Scores for certain symptom scales in the larger CTV group (i.e.fatigue, pain and financial difficulties) showed a statistically significant deterioration compared with the smaller CTV group.
Conclusions : In patients with BSTSs unsuitable for surgery, especially in small CTV group, CIRT yielded an acceptable tumor control and QOL levels remained at relatively good levels after CIRT for at least 12 months.
|
